💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Pluristem up 6% ahead of PLX-PAD data readout

Published 06/04/2018, 10:53 AM
© Reuters.  Pluristem up 6% ahead of PLX-PAD data readout
PLUR
-
  • Thinly traded micro cap Pluristem (PSTI +5.9%) is up on more than a 4x surge in volume on the heels of its announcement that it will release topline data from its Phase 2 clinical trial assessing PLX-PAD cells in intermittent claudication (IC) on Tuesday, June 12. IC, a subset of peripheral artery disease, is caused by restricted blood flow in the legs leading to muscle pain, cramping, numbness and a sense of fatigue, commonly in the calf muscle.
  • The primary endpoint is the change in maximum walking distance one year after the first treatment with PLX-PAD.
  • Previously: Pluristem completes enrollment in mid-stage study of PLX-PAD cells in peripheral arterydisease (Jan. 12, 2017)
  • Now read: Rounds Report: Nektar Rallied Aggressively While Lexicon Experienced Significant Insider Purchases


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.